Drug intelligence / Profile preview

CC-11006

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

CC‑11006 is a proprietary, orally available small molecule and thalidomide analog developed as an immunomodulatory and antineoplastic agent. It acts as a cereblon (CRBN) modulator with potential to modulate the expression of proinflammatory and regulatory cytokines. Its mechanisms include immunomodulation, inhibition of interleukin 1 beta and tumor necrosis factor, and stimulation of interleukin 10. The drug was primarily investigated for inflammatory disorders and hematological malignancies such as myelodysplastic syndromes (MDS), but development has been discontinued after reaching phase 1 clinical trials[1][2][3][4][5].

Other names: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)methyl)cyclopropanecarboxamide444287-44-9UNII-6DC9826KIMUNII6DC9826KIMUNII 6DC9826KIM

Targets

CRBN (Cereblon)

Beyond the preview

Go deeper on CC-11006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-11006.

Explore the full profile